Gilead Announces FDA Priority Review Designation For Sofosbuvir/Velpatasvir

January 5, 2016
1 min read

The FINANCIAL — Gilead Sciences, Inc. on January 4 announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi in December 2013, and velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.

Gilead filed the NDA for SOF/VEL on October 28, 2015, and FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 28, 2016.

The FDA has assigned SOF/VEL a Breakthrough Therapy designation, which is granted to investigational medicines that may offer major advances in treatment over existing options. The NDA for SOF/VEL is supported by data from four Phase 3 ASTRAL trials, which evaluated the fixed-dose combination in hepatitis C genotypes 1-6. A marketing application for SOF/VEL is also under review in the European Union, and was validated by the European Medicines Agency (EMA) in December. The SOF/VEL fixed-dose combination is an investigational product and its safety and efficacy have not been established, according to Gilead.

 

Leave a Reply

Related stories


Fatal error: Uncaught Error: Call to a member function have_posts() on null in /home/slonfcxh/public_html/wp-content/themes/fox/data/archive.php:731 Stack trace: #0 /home/slonfcxh/public_html/wp-content/themes/fox/widgets/latest-posts/widget.php(273): fox56_blog_list() #1 /home/slonfcxh/public_html/wp-content/themes/fox/widgets/latest-posts/register.php(33): include('/home/slonfcxh/...') #2 /home/slonfcxh/public_html/wp-includes/class-wp-widget.php(394): Wi_Widget_Latest_Posts->widget() #3 /home/slonfcxh/public_html/wp-includes/widgets.php(847): WP_Widget->display_callback() #4 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(418): dynamic_sidebar() #5 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(136): fox56_single_sidebar() #6 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(7): fox56_single_inner() #7 /home/slonfcxh/public_html/wp-content/themes/fox/single.php(23): fox56_single() #8 /home/slonfcxh/public_html/wp-includes/template-loader.php(132): include('/home/slonfcxh/...') #9 /home/slonfcxh/public_html/wp-blog-header.php(19): require_once('/home/slonfcxh/...') #10 /home/slonfcxh/public_html/index.php(17): require('/home/slonfcxh/...') #11 {main} thrown in /home/slonfcxh/public_html/wp-content/themes/fox/data/archive.php on line 731